Detalles de la búsqueda
1.
Homologous recombination deficiency should be tested for in patients with advanced stage high-grade serous ovarian cancer aged 70 years and over.
Gynecol Oncol
; 187: 221-226, 2024 May 30.
Artículo
en Inglés
| MEDLINE | ID: mdl-38821039
2.
Phase II trial of pembrolizumab and epacadostat in recurrent clear cell carcinoma of the ovary: An NRG oncology study GY016.
Gynecol Oncol
; 186: 61-68, 2024 Apr 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-38603953
3.
Health-related quality of life in patients with newly diagnosed advanced ovarian cancer treated with niraparib vs placebo: Results from the phase 3 randomized PRIMA/ENGOT-OV26/GOG-3012 trial.
Gynecol Oncol
; 184: 168-177, 2024 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-38325276
4.
Lifestyle intervention in ovarian cancer enhanced survival (LIVES) study (NRG/GOG0225): Recruitment, retention and baseline characteristics of a randomized trial of diet and physical activity in ovarian cancer survivors.
Gynecol Oncol
; 170: 11-18, 2023 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-36608382
5.
Adjuvant Chemotherapy plus Radiation for Locally Advanced Endometrial Cancer.
N Engl J Med
; 380(24): 2317-2326, 2019 06 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-31189035
6.
Secondary Surgical Cytoreduction for Recurrent Ovarian Cancer.
N Engl J Med
; 381(20): 1929-1939, 2019 11 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-31722153
7.
Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer.
N Engl J Med
; 381(25): 2403-2415, 2019 12 19.
Artículo
en Inglés
| MEDLINE | ID: mdl-31562800
8.
Patient reported outcomes for cisplatin and radiation followed by carboplatin/paclitaxel versus carboplatin/paclitaxel for locally advanced endometrial carcinoma: An NRG oncology study.
Gynecol Oncol
; 164(2): 428-436, 2022 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-34903380
9.
Adjuvant Therapy in Node-Positive Endometrial Cancer: A Focus on Chemotherapy.
Curr Oncol Rep
; 24(12): 1677-1683, 2022 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-36417134
10.
Patient-centred outcomes and effect of disease progression on health status in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation receiving maintenance olaparib or placebo (SOLO1): a randomised, phase 3 trial.
Lancet Oncol
; 22(5): 632-642, 2021 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-33862001
11.
Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trial.
Lancet Oncol
; 22(12): 1721-1731, 2021 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-34715071
12.
Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer.
N Engl J Med
; 379(26): 2495-2505, 2018 12 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-30345884
13.
Tolerability of maintenance olaparib in newly diagnosed patients with advanced ovarian cancer and a BRCA mutation in the randomized phase III SOLO1 trial.
Gynecol Oncol
; 163(1): 41-49, 2021 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-34353615
14.
Bevacizumab plus fosbretabulin in recurrent ovarian cancer: Overall survival and exploratory analyses of a randomized phase II NRG oncology/gynecologic oncology group study.
Gynecol Oncol
; 159(1): 79-87, 2020 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-32723679
15.
Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial.
Lancet Oncol
; 20(5): 636-648, 2019 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-30948273
16.
Weekly vs. Every-3-Week Paclitaxel and Carboplatin for Ovarian Cancer.
N Engl J Med
; 374(8): 738-48, 2016 Feb 25.
Artículo
en Inglés
| MEDLINE | ID: mdl-26933849
17.
Shaping the standard of care in ovarian cancer management: A review of Gynecologic Oncology Group (GOG)/NRG oncology clinical trials of the past twenty years.
Gynecol Oncol
; 153(3): 479-486, 2019 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-30905435
18.
Multiple biomarker algorithms to predict epithelial ovarian cancer in women with a pelvic mass: Can additional makers improve performance?
Gynecol Oncol
; 154(1): 150-155, 2019 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-30992143
19.
GOG 8020/210: Risk stratification of lymph node metastasis, disease progression and survival using single nucleotide polymorphisms in endometrial cancer: An NRG oncology/gynecologic oncology group study.
Gynecol Oncol
; 153(2): 335-342, 2019 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-30827726
20.
An NRG Oncology/GOG study of molecular classification for risk prediction in endometrioid endometrial cancer.
Gynecol Oncol
; 148(1): 174-180, 2018 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-29132872